Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with…
Read the full articleYou might also wanna read
Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update
Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost cle
Icotrokinra Maintains Psoriasis Skin Clearance Through 52 Weeks
One-year Phase III data show icotrokinra delivered durable skin clearance and symptom improvement in adults with moderate-to-severe plaque p
Abrocitinib Boosts Skin Clearance and Itch Relief in AD
Abrocitinib can help achieve minimal disease activity in patients with atopic dermatitis irrespective of previous exposure to dupilumab, a p
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Conditions : Primary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis (PSC); Atopic Dermatitis (AD) Interventions : Drug: Upadaciti
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Conditions : Plaque Psoriasis; Metabolic Dysfunction-Associated Steatotic Liver Disease Sponsors : Novartis Pharmaceuticals Not yet recruiti
Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
A phase 2 trial of InnoCare Pharma’s TYK2 inhibitor soficitinib in nonsegmental vitiligo has hit its primary endpoint, clearing the Chinese
Comments
Sign in to join the conversation.
No comments yet. Be the first.